Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA VP becomes Senate Democratic staffer

Executive Summary

The Democratic staff of the Senate Finance Committee names Pharmaceutical Research & Manufacturers of America VP-Affordability & Access Committee Michelle Easton as chief of the Health & Welfare Team. Easton joined PhRMA in February 2005, heading up the team's public education and advocacy efforts (1"The Pink Sheet" March 14, 2005, p. 3). From 1997-2003, Easton worked for former Sen. John Breaux (D-La.) as legislative director and counsel and as the Senate Aging Committee's staff director. Prior to working for Breaux, Easton worked as healthcare legislative aid to PhRMA CEO Billy Tauzin while he served in Congress...

You may also be interested in...



PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel